Wang Qin, Xing Mao, Deng Lijuan, Wang Yongsheng, Mukaram Kipaytul, Xu Xiaoyu
College of Pharmacy, Southwest University Chongqing Pharmacodynamic Evaluation of Engineering Research Center, Chongqing 400715, China.
Zhongguo Zhong Yao Za Zhi. 2012 Jun;37(11):1677-81.
To investigate the distribution process of puerarin contained in Zige freeze-dried powder injection in rat liver and kidney and the safety of Zige freeze-dried powder injection.
Rats were divided into the Zige freeze-dried powder injection group and the puerarin freeze-dried powder injection control group randomly. The liver and kidney samples were collected at 5, 10, 20, 30, 45, 60 and 120 min after intravenous administration of puerarin (26.7 microg x g(-1)) through caudal vein and detected by HPLC.
The concentration of puerarin in kidney reached the max value of 58.12 microg x g(-1) for the Zige freeze-dried powder injection group and 71.28 microg x g(-1) for the Puerarin freeze-dried powder injection group. The value of AUC(0-2h) was 26.24 microg x h x g(-1) for the Zige freeze-dried powder injection group and 35.24 microg x h x g(-1) for the puerarin freeze-dried powder injection group, MRT(0-2h) was 0. 39 h for the Zige freeze-dried powder injection group and 0. 42 h for the puerarin freeze-dried powder injection control group. Compared with the control group, the Zige freeze-dried powder injection group showed a significant decrease in Cmax and AUC(0-2h) (P < 0.05), with no notable difference in peak time tmax and MRT(0-2h). The two groups showed no obvious difference in tmax Cmax, AUC(0-2h) and MRT(0-2h) of puerarin in rat kidney.
Compared with Zige freeze-dried powder injection, Zige freeze-dried powder injection can reduce the distribution of puerarin in rat kidney, with no obvious change in the elimination of puerarin in rat kidney. It also showed no significant change in distribution and elimination in liver. This indicates that Zige freeze-dried powder injection is safer to kidney than puerarin freeze-dried powder injection.
研究紫葛冻干粉针剂中葛根素在大鼠肝肾中的分布过程及紫葛冻干粉针剂的安全性。
将大鼠随机分为紫葛冻干粉针剂组和葛根素冻干粉针剂对照组。通过尾静脉静脉注射葛根素（26.7μg·g⁻¹）后，于5、10、20、30、45、60和120分钟采集肝肾样本，并用高效液相色谱法进行检测。
紫葛冻干粉针剂组大鼠肾脏中葛根素浓度最大值为58.12μg·g⁻¹，葛根素冻干粉针剂对照组为71.28μg·g⁻¹。紫葛冻干粉针剂组的AUC(0 - 2h)值为26.24μg·h·g⁻¹，葛根素冻干粉针剂组为35.24μg·h·g⁻¹；紫葛冻干粉针剂组的MRT(0 - 2h)为0.39小时，葛根素冻干粉针剂对照组为0.42小时。与对照组相比，紫葛冻干粉针剂组的Cmax和AUC(0 - 2h)显著降低（P < 0.05），峰时间tmax和MRT(0 - 2h)无显著差异。两组大鼠肾脏中葛根素的tmax、Cmax、AUC(0 - 2h)和MRT(0 - 2h)无明显差异。
与葛根素冻干粉针剂相比，紫葛冻干粉针剂可减少葛根素在大鼠肾脏中的分布，大鼠肾脏中葛根素的消除无明显变化。其在肝脏中的分布和消除也无显著变化。这表明紫葛冻干粉针剂对肾脏的安全性优于葛根素冻干粉针剂。
